Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a biomarker for osteosarcoma treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| sB7-H3 of treatment-naive osteosarcoma patients | Before delivering neoadjuvant chemotherapy, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood |
| |
| sB7-H3 after neoadjuvant chemotherapy for osteosarcoma patients | After neoadjuvant chemotherapy and before definitive surgery, using ELISA to test the protein expression of sB7-H3 of Peripheral Blood |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ELISA: enzyme-linked immunosorbent assay | Diagnostic Test | enzyme-linked immunosorbent assay |
|
| Measure | Description | Time Frame |
|---|---|---|
| correlation of quantity of Protein B7-H3 Expression with clinical evaluation | Clinical evaluation according to RECIST 1.1 | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| correlation of quantity of Protein B7-H3 Expression with histological responses | Histological responses according to Huvos Grade | 6 months |
| correlation of quantity of Protein B7-H3 Expression with event-free survival |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Initial treated osteosarcoma patients in PKUPH and later would recieve definitive surgery in PKUPH with complete clinical materials.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lu Xie, M.D. | Contact | +86-13401044719 | xie.lu@hotmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking University People's Hospital | Recruiting | Beijing | Beijing Municipality | 100044 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30123093 | Background | Wang L, Kang FB, Zhang GC, Wang J, Xie MF, Zhang YZ. Clinical significance of serum soluble B7-H3 in patients with osteosarcoma. Cancer Cell Int. 2018 Aug 13;18:115. doi: 10.1186/s12935-018-0614-z. eCollection 2018. | |
| 36519392 | Background | Xie L, Chen C, Liang X, Xu J, Sun X, Sun K, Yang R, Tang X, Guo W. Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy. Orthop Surg. 2023 Mar;15(3):829-838. doi: 10.1111/os.13620. Epub 2022 Dec 15. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018450 | Disease Progression |
| D012516 | Osteosarcoma |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D018213 | Neoplasms, Bone Tissue |
Not provided
Not provided
Not provided
Not provided
Not provided
event-free survival calculated from starting systemic therapy to any tumor-related events for progression
| 2 years |
| correlation of quantity of Protein B7-H3 Expression with overall survival | overall survival calculated from starting systemic therapy to death | 5 years |
| D009372 | Neoplasms, Connective Tissue |
| D018204 | Neoplasms, Connective and Soft Tissue |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D012509 | Sarcoma |